Track InnoCare Pharma Limited's EBIT ($1.2B) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Sep 30, 2026
Trailing 12 months ending Sep 30, 2026
InnoCare Pharma Limited (INCPF) currently reports a EBIT of $1.2B as of September 2026. That compares with $-290M in the prior-year period — up 512.7% year over year. That is below the Healthcare sector average of $1.1T. Use the charts on this page to explore InnoCare Pharma Limited's EBIT history and peer comparisons.
InnoCare Pharma Limited's EBIT increased from $-290M to $1.2B — a 512.7% year-over-year increase (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
InnoCare Pharma Limited's EBIT of $1.2B is lower than the Healthcare sector average of $1.1T. That is roughly 99.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
InnoCare Pharma Limited reported $1.2B in EBIT as of September 2026. That compares with $-290M in the prior-year period — up 512.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current EBIT of $1.2B, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $1.1T. From there, open related valuation or income-statement pages for InnoCare Pharma Limited, and consider following INCPF for alerts when major investors trade the stock.